MARKET

TVGNW

TVGNW

Tevogen Bio
NASDAQ
0.0579
-0.0059
-9.25%
Closed 15:58 03/25 EDT
OPEN
0.0501
PREV CLOSE
0.0638
HIGH
0.0615
LOW
0.0454
VOLUME
392.39K
TURNOVER
436
52 WEEK HIGH
0.1499
52 WEEK LOW
0.0099
MARKET CAP
--
P/E (TTM)
0.1580
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TVGNW last week (0317-0321)?
Weekly Report · 2d ago
Weekly Report: what happened at TVGNW last week (0310-0314)?
Weekly Report · 03/17 09:38
TEVOGEN BIO ANNOUNCES UNIQUE T CELL VACCINE UNDER DEVELOPMENT AND FILES PATENT WITH THE USPTO
Reuters · 03/10 16:40
Weekly Report: what happened at TVGNW last week (0303-0307)?
Weekly Report · 03/10 09:39
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Barchart · 03/07 15:09
Weekly Report: what happened at TVGNW last week (0224-0228)?
Weekly Report · 03/03 09:39
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Barchart · 02/28 12:17
Weekly Report: what happened at TVGNW last week (0217-0221)?
Weekly Report · 02/24 09:39
More
About TVGNW
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

Webull offers Tevogen Bio Holdings Inc stock information, including NASDAQ: TVGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVGNW stock methods without spending real money on the virtual paper trading platform.